Polycystic Kidney, Autosomal Dominant
Information
- Disease name
- Polycystic Kidney, Autosomal Dominant
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00410007 | Completed | N/A | The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease | October 2006 | November 2011 |
| NCT00413777 | Completed | Phase 2 | Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | December 2005 | June 2010 |
| NCT00426153 | Completed | Phase 2/Phase 3 | Octreotide in Severe Polycystic Liver Disease | January 2007 | October 2008 |
| NCT00456365 | Completed | Phase 3 | Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | November 2006 | October 2012 |
| NCT00565097 | Completed | Phase 2/Phase 3 | Lanreotide as Treatment of Polycystic Livers | October 2007 | |
| NCT01114594 | Completed | Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease | April 2010 | April 2012 | |
| NCT01233869 | Completed | Phase 2 | Bosutinib For Autosomal Dominant Polycystic Kidney Disease | December 2010 | August 2014 |
| NCT01559363 | Completed | Phase 1/Phase 2 | A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease | October 11, 2012 | February 8, 2019 |
| NCT03803124 | Completed | Phase 3 | Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD | December 2015 | December 15, 2017 |
| NCT04023214 | Completed | The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease | July 25, 2011 | December 31, 2018 | |
| NCT04363554 | Completed | N/A | The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease | September 25, 2017 | April 20, 2020 |
| NCT04407481 | Completed | PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) | November 1, 2020 | October 13, 2022 | |
| NCT04534985 | Completed | N/A | Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease | February 9, 2021 | March 31, 2023 |
| NCT02021110 | Completed | Phase 2 | Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease | December 2013 | October 2015 |
| NCT02251275 | Completed | Phase 3 | Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | October 17, 2014 | November 9, 2018 |
| NCT02494141 | Completed | Phase 4 | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | November 12, 2015 | February 1, 2021 |
| NCT02656017 | Completed | Phase 2 | Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease | June 27, 2016 | December 7, 2020 |
| NCT02847624 | Completed | Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD | March 24, 2014 | September 20, 2022 | |
| NCT02903511 | Completed | Phase 2 | Feasibility Study of Metformin Therapy in ADPKD | November 2016 | August 17, 2020 |
| NCT03342742 | Completed | N/A | Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease | June 4, 2018 | October 13, 2020 |
| NCT03687554 | Completed | Phase 1 | Effect of Venglustat in Patients With Renal Impairment | October 5, 2018 | February 27, 2019 |
| NCT05521191 | Recruiting | Phase 1 | A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease | October 6, 2022 | June 2025 |
| NCT05510115 | Recruiting | Phase 2 | Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease | November 18, 2022 | March 31, 2026 |
| NCT01589705 | Terminated | The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease | January 2012 | April 2012 | |
| NCT03523728 | Terminated | Phase 2/Phase 3 | A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients | October 4, 2018 | August 3, 2021 |
| NCT04310319 | Unknown status | N/A | Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt | September 7, 2020 | October 2021 |
- ICD10 preferred id (Insert disease from ICD10)
- D0013920
- ICD10 class code (Insert disease from ICD10)
- Q61.2
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016891